Clinical Trials

Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer 

ENGOT-EN1/FANDANGO: A Randomized Phase II Trial of First-line Combination Chemotherapy With Nintedanib / Placebo for Patients With Advanced or Recurrent Endometrial Cancer 

Radiation Therapy with or without Cisplatin in Treating Patients with Recurrent Endometrial Cancer

An international phase III randomised study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemotherapy

A prospective randomized Phase III trial of carboplatin/gemcitabine/bevacizumab vs. carbolatin/pegylated liposomal doxorubin/bevacizumab in patients with platinum-sensitive recurrent ovarian cancer 

Atezolizumab With Bevacizumab and Chemotherapy vs Bevacizumab and Chemotherapy in Early Relapse Ovarian Cancer

A randomized trial evaluating cytoreductive surgery in patients with platinum-sensitive recurrent ovarian cancer

Atezolizumab vs Placebo Phase III Study in Late Relapse Ovarian Cancer Treated With Chemotherapy+Bevacizumab

Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 200kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer

Carboplatin and Paclitaxel With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer

A randomised trial of concurrent cediranib [AZD2171] (with platinum-based chemotherapy) and maintenance cediranib in women with platinum-sensitive relapsed ovarian cancer. 

Phase III international, randomized study of Trabectedin plus Pegylated Liposomal Doxorubicin (PLD) versus Carboplatin plus PLD in patients with ovarian cancer progressing within 6-12 months of last platinum

An umbrella study of biomarker-driven targeted therapy in patients with platinum-resistant recurrent ovarian cancer

A single-arm phase II study of niraparib and bevacizumab maintenance therapy in platinum-sensitive ovarian cancer patients previously treated with a PARP inhibitor 

Prospective Multi-institutional Phase III Trial of Salvage Systemic Therapy with or without Stereotactic Ablative Radiation Therapy for Recurrent Ovarian Cancer

Liposomal doxorubicin stealth vs. carboplatin/paclitaxel in recurrent ovarian cancer patients with platinum-free interval between 6-12 months 

Phase III study Olaparib Maintenance Retreatment in Patients With Epithelial Ovarian Cancer

Phase III Randomised, Double Blind, Placebo Controlled Study of Olaparib Maintenence Monotherapy in Platinum Sensitive relapsed BRCA Mutated Ovarian Cancer Patients With a Complete or Partial Response Following Platinum Based Chemotherapy

A Randomised Phase II Study Of Nintedanib (BIBF1120) Compared To Chemotherapy in Patients With Recurrent Clear Cell Carcinoma Of The Ovary Or Endometrium

Long-term survival with gynecological cancer